~~<i id='403D6C34B9'><strike id='403D6C34B9'><tt id='403D6C34B9'><pre id='403D6C34B9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：hotspot 2025-10-02 23:48:19 - browse：1255

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The new HIV moral panic

focus

knowledge

focus

leisure time

knowledge

FranvanDelftforGalapagosSeekingtodifferentiateitselffromothermakersofCAR-Tcancertherapies,GalapagosN

WSS

Free medical tuition alone isn't enough to close gaps in primary care

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Abbott's new stent may help patients with peripheral artery disease

Who gets to use the title 'doctor'?

Can CDC director Mandy Cohen drive consensus in Washington?

STAT series 'Denied by AI' wins major journalism prizes

focus

hotspot

focus

Dobbs anniversary: the lost opportunity of abortion as health care

CVS is willing to dump 10% of its Medicare Advantage members

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The White House hikes tariffs on plastic syringes made in China

How to save PrEP access — and even expand it

Eli Lilly to acquire Versanis in heated race for weight loss drugs

How to save PrEP access — and even expand it

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Tori Bowie and the unacceptable rates of Black maternal death

Argenx drug significantly slows progression of nerve disorder

focus

Involuntary treatment for addiction doesn't work

As H5N1 spreads in cows, experts warn against drinking raw milk

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Care demand spikes challenge UnitedHealth’s provider arm

Ripples from Flovent's discontinuation is killing children with asthma

Cherokee Nation medical school graduates its first class

knowledge

focus

leisure time

knowledge